Parisi M T, Matthay K K, Huberty J P, Hattner R S
Department of Radiology, University of California, San Francisco.
Radiology. 1992 Aug;184(2):463-7. doi: 10.1148/radiology.184.2.1620849.
Iodine-131 metaiodobenzylguanidine (MIBG) has shown effectiveness as a systemic radiotherapeutic agent in neuroblastoma. The authors postulated a likely dose-related relationship of MIBG sensitivity when it was administered for neuroblastoma detection. They studied this relationship in neuroblastoma patients who underwent scanning after receiving diagnostic and therapeutic doses of MIBG in temporal proximity. Seven patients with stage IV disease received a total of 14 therapeutic administrations of I-131 MIBG (150-350 mCi [5,550-12,950 MBq]/m2 per treatment). Posttherapy scans were obtained at 3 and at 5-7 days. Diagnostic MIBG scans had been obtained no more than 4 weeks before the start of therapy. Use of diagnostic MIBG scanning led to underestimation of the tumor burden by 50% compared with use of posttherapy scanning. This difference may be an important consideration in selecting therapeutic strategies for individual patients. It further suggests that use of much larger diagnostic doses of MIBG is a rational strategy in histologically confirmed cases of advanced disease.
碘-131间碘苄胍（MIBG）已显示出作为神经母细胞瘤全身放射治疗剂的有效性。作者推测，在用于神经母细胞瘤检测时，MIBG敏感性可能与剂量相关。他们在接受诊断和治疗剂量的MIBG后不久进行扫描的神经母细胞瘤患者中研究了这种关系。7例IV期疾病患者共接受了14次I-131 MIBG治疗给药（每次治疗150 - 350 mCi [5550 - 12950 MBq]/m²）。治疗后扫描在3天以及5 - 7天进行。诊断性MIBG扫描在治疗开始前不超过4周进行。与使用治疗后扫描相比，使用诊断性MIBG扫描导致肿瘤负荷低估50%。这种差异可能是为个体患者选择治疗策略时的一个重要考虑因素。这进一步表明，在组织学确诊的晚期疾病病例中，使用大得多的诊断剂量的MIBG是一种合理的策略。
